Molecular mechanisms of lithium action on kinases
Molecular mechanisms of lithium action on kinases
批准号:
10705786
负责人:
PETER S KLEIN
金额:
$31.56万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-09-17 至 2026-08-31
关键词:
AddressAdvocateAffectAffinityBase PairingBenchmarkingBindingBinding ProteinsBiochemicalBioinformaticsBiologicalBiophysicsBipolar DisorderBloodCalibrationCatalytic DomainChemicalsChemistryCyclic AMP-Dependent Protein KinasesDementiaDevelopmentDoseEnzymesEquilibriumExperimental DesignsExposure toFoundationsFree EnergyFutureGenesGlycogen Synthase Kinase 3GoalsGrowthHumanIn VitroIndividualIonsLithiumMapsMedicalMethodsMolecularMutagenesisMutagensMutationNatural SelectionsOutcomePathway interactionsPersonsPhenotypePhosphoric Monoester HydrolasesPhosphotransferasesPhysiologicalPhysiological ProcessesPredispositionProcessProtein KinaseProteinsProtocols documentationQuantum MechanicsReactionResistanceSamplingSignal PathwaySiteStatistical BiasTherapeuticTimeVariantYeastsbiophysical techniquesdesigndietary trace elementdosageenzyme mechanismenzyme modelexperimental studyglycogen synthase kinase 3 betaimprovedin vivoinsightmechanical energymolecular mechanicsmutation screeningpatient responseside effectsimulation
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Summary/Abstract
Lithium is a first-line therapy for millions of people suffering from bipolar disorder, and is promising for
inhibiting development of dementia. Experiments show that a primary mode by which Li+ alters physiological
processes is by reducing activities of a surprisingly limited number of Mg2+-dependent phosphoryl-transferring
enzymes, including phosphomonoesterases and protein kinases. While the (Li-independent) catalytic
mechanisms of these enzymes are quite well-understood, much about the mechanistic details underlying their
Li-susceptibility remain unknown. Not surprisingly, it remains a major challenge to design enzyme variants that
are Li-resistant, and use them to disentangle signaling pathways associated with Li-susceptibilities of individual
enzymes. Here we focus on Li+'s action on kinases, and address the following problem central to alleviating the
issues raised above. Experiments on 71 human kinases show a wide range of Li-susceptibility — many are
unaffected and others are affected to varying degrees. But there is no explanation for these variations.
We address this gap in our understanding of Li-action by using state-of-the-art molecular mechanics
(MM), quantum mechanics (QM) and QM/MM simulations, as well as mutagenesis experiments guided by
bioinformatics and natural selection. Supported by experiments, we explore the overarching hypothesis that Li+
affects kinase activity by interacting directly with their catalytic sites. In Aim 1, simulations will examine how Li+
binds kinases, and how Li+ binding reduces kinase activity. Additionally, simulations will provide insights into
potential allosteric effects that regulate catalytic site activity. Our biochemical, cellular and in vivo experiments
in Aim2 are designed to (i) systematically examine effects of sequence differences between Li-sensitive and Li-
resistant kinases, with the goal of making a Li-sensitive enzyme, GSK-3, resistant to Li+; and (ii) discover key
residues that make certain kinases Li-sensitive. Experiments will also validate findings from simulations, and at
the same time, simulations will provide molecular insights to interpret results from mutational experiments.
Combined analysis of results from simulations and experiments will yield a Li-resistant GSK-3, which is
significant because it will, for the first time, enable us to disentangle GSK-3-driven physiological effects of Li+
from those of other Li-sensitive enzymes. This study will also provide a physical basis to explain observed
variations of Li-sensitivity across kinases, and these biophysical findings will serve as foundations for future
efforts to make other Li-sensitive kinases resistant to Li+, and map their specific phenotypes. We expect that
such efforts will improve understanding and predictions of patient responses to Li-treatments and dosages,
which remains a difficult task. This will both expedite therapy and avoid exposure to side effects. Finally, this
study will explore new advancements in modeling enzyme reactions and yield a validated polarizable force
field for describing Li+/Mg2+ interactions with proteins. This will enable future reliable studies of Li-action on
proteins not considered in this project and broaden exploration of the full range of Mg-binding proteins.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting splicing in myelodysplasia through GSK-3
-
批准号:10677505
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2022
-
负责人:PETER S KLEIN
-
依托单位:
Molecular mechanisms of lithium action on kinases
-
批准号:10500972
-
项目类别:
-
资助金额:$32.51万
-
财政年份:2022
-
负责人:PETER S KLEIN
-
依托单位:
Targeting Coronavirus through Nucleocapsid Phosphorylation
-
批准号:10239590
-
项目类别:
-
资助金额:$44.69万
-
财政年份:2021
-
负责人:PETER S KLEIN
-
依托单位:
Maintenance and expansion of long-term hematopoietic stem cells
-
批准号:9767274
-
项目类别:
-
资助金额:$54.03万
-
财政年份:2018
-
负责人:PETER S KLEIN
-
依托单位:
The Penn-StARR Program for Research in Residency
-
批准号:10321397
-
项目类别:
-
资助金额:$34.94万
-
财政年份:2018
-
负责人:PETER S KLEIN
-
依托单位:
Maintenance and expansion of long-term hematopoietic stem cells
-
批准号:10162647
-
项目类别:
-
资助金额:$54.03万
-
财政年份:2018
-
负责人:PETER S KLEIN
-
依托单位:
An unexpected signaling output for the tumor suppressor APC
-
批准号:9353834
-
项目类别:
-
资助金额:$31.4万
-
财政年份:2016
-
负责人:PETER S KLEIN
-
依托单位:
An unexpected signaling output for the tumor suppressor APC
-
批准号:9753259
-
项目类别:
-
资助金额:$31.4万
-
财政年份:2016
-
负责人:PETER S KLEIN
-
依托单位:
An unexpected signaling output for the tumor suppressor APC
-
批准号:9504746
-
项目类别:
-
资助金额:$8.29万
-
财政年份:2016
-
负责人:PETER S KLEIN
-
依托单位:
Regulation of Neurogenesis and Behavior by GSK-3
-
批准号:9001371
-
项目类别:
-
资助金额:$45.76万
-
财政年份:2014
-
负责人:PETER S KLEIN
-
依托单位:
Regulation of Neurogenesis and Behavior by GSK-3
-
批准号:8652557
-
项目类别:
-
资助金额:$52.06万
-
财政年份:2014
-
负责人:PETER S KLEIN
-
依托单位:
Regulation of Neurogenesis and Behavior by GSK-3
-
批准号:8791140
-
项目类别:
-
资助金额:$45.21万
-
财政年份:2014
-
负责人:PETER S KLEIN
-
依托单位:
Regulation of neurogenesis and behavior by GSK-3
-
批准号:8665030
-
项目类别:
-
资助金额:$39.1万
-
财政年份:2013
-
负责人:PETER S KLEIN
-
依托单位:
Targeting Wnt and mTOR to expand hematopoietic stem cells
-
批准号:8088551
-
项目类别:
-
资助金额:$24.0万
-
财政年份:2011
-
负责人:PETER S KLEIN
-
依托单位:
Regulating Hematopoietic Stem Cell Homeostasis through GSK-3
-
批准号:8210662
-
项目类别:
-
资助金额:$54.3万
-
财政年份:2011
-
负责人:PETER S KLEIN
-
依托单位:
Targeting Wnt and mTOR to expand hematopoietic stem cells
-
批准号:8248167
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2011
-
负责人:PETER S KLEIN
-
依托单位:
Regulating Hematopoietic Stem Cell Homeostasis through GSK-3
-
批准号:8461299
-
项目类别:
-
资助金额:$50.23万
-
财政年份:2011
-
负责人:PETER S KLEIN
-
依托单位:
Regulating Hematopoietic Stem Cell Homeostasis through GSK-3
-
批准号:8656762
-
项目类别:
-
资助金额:$51.3万
-
财政年份:2011
-
负责人:PETER S KLEIN
-
依托单位:
Regulating Hematopoietic Stem Cell Homeostasis through GSK-3
-
批准号:8304987
-
项目类别:
-
资助金额:$52.36万
-
财政年份:2011
-
负责人:PETER S KLEIN
-
依托单位:
Early activation of the zygotic genome
-
批准号:7145079
-
项目类别:
-
资助金额:$29.85万
-
财政年份:2006
-
负责人:PETER S KLEIN
-
依托单位:
海外基金